Krystal Biotech Stock Price, News & Analysis

Jeune Aesthetics, a subsidiary of Krystal Biotech (NASDAQ: KRYS), announced positive interim safety and efficacy results from Phase 1 study PEARL-1 for KB301, an investigational aesthetic treatment. The study evaluated KB301 for improving lateral canthal lines and dynamic wrinkles of the décolleté.

Key findings include:

• 94% of décolleté subjects showed improvement in wrinkles after two months
• 75% of lateral canthal subjects showed improvement in wrinkles after two months
• Improvements were also seen in crepiness, hydration, and radiance
• The safety profile was consistent with prior clinical experience

Based on these results, Jeune will progress KB301 into Phase 2 development for treating dynamic wrinkles of the décolleté. A conference call to discuss results is scheduled for August 28, 2024.

Krystal Biotech (NASDAQ: KRYS) reported strong Q2 2024 financial results, with net product revenue of $70.3 million, up 55.3% from Q1. VYJUVEK, their treatment for Dystrophic Epidermolysis Bullosa, has generated $166.2 million since launch in August 2023. The company secured over 400 reimbursement approvals in the U.S., with 97% positive access determinations for commercial and Medicaid plans. Krystal ended Q2 with $628.9 million in cash and investments.

The company expects three clinical readouts in H2 2024, including KB301 for aesthetics, KB408 for alpha-1 antitrypsin deficiency, and KB707 for solid tumors. Krystal is advancing its pipeline across respiratory, ophthalmology, oncology, and dermatology indications. For FY2024, they anticipate $150-$175 million in non-GAAP R&D and SG&A expenses.

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has announced it will release its second quarter 2024 financial results on August 5, 2024, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update.

Investors and the public can access the live webcast at a provided link. For those unable to attend, a replay will be available for 30 days on the company's website. This announcement indicates Krystal Biotech's commitment to transparency and shareholder communication, as it prepares to share its latest financial performance and operational progress.

Krystal Biotech (NASDAQ: KRYS) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. CEO Krish S. Krishnan will participate in a fireside chat at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available on the company's website.

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, announced its participation in the American Thoracic Society (ATS) 2024 International Conference from May 17-22 in San Diego, CA. The company will present new preclinical data on respiratory genetic medicine candidates KB407 and KB408. Both are modified, replication-defective, non-integrating HSV-1 vectors designed for inhaled lung delivery via nebulization. KB407 aims to treat cystic fibrosis, while KB408 targets alpha-1 antitrypsin deficiency. Data on these candidates will be shared, including insights from ongoing Phase 1 studies. Poster presentations by Dr. Sara Artusi will provide further details.

Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the BofA Securities 2024 Health Care Conference where Chairman and CEO Krish S. Krishnan will engage in a fireside chat and host investor meetings. The webcast of the presentation will be available on the Company's website.

Krystal Biotech, Inc. reported $45.3 million in net product revenue for 1Q 2024. The company is focused on delivering genetic medicines for rare diseases like Dystrophic Epidermolysis Bullosa. With a strong financial position and positive performance in clinical trials, Krystal Biotech is poised for growth. Key developments include progress with VYJUVEK, successful clinical studies in Japan, and ongoing trials for cystic fibrosis and alpha-1 antitrypsin deficiency treatments. The company also received FDA Fast Track Designation for inhaled KB707 for lung tumors. Financially, the company recorded $622.3 million in cash and investments with a net income of $0.9 million for 1Q 2024.

Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.